• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亚胺培南-西司他丁在新生儿中的单剂量药代动力学。

Single-dose pharmacokinetics of imipenem-cilastatin in neonates.

作者信息

Gruber W C, Rench M A, Garcia-Prats J A, Edwards M S, Baker C J

出版信息

Antimicrob Agents Chemother. 1985 Apr;27(4):511-4. doi: 10.1128/AAC.27.4.511.

DOI:10.1128/AAC.27.4.511
PMID:3859243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC180086/
Abstract

The single-dose pharmacokinetics of imipenem (N-formimidoyl thienamycin), a beta-lactam antibiotic, used in combination with cilastatin, a renal dehydropeptidase I inhibitor, were evaluated in 10 neonates 1 to 8 days of age. The imipenem-cilastatin combination was given intravenously over a 15-min period at a dose of 15 or 25 mg/kg. Drug concentrations in serum, urine, and cerebrospinal fluid (when available) were determined by high-pressure liquid chromatography, and plasma disposition of the drugs was described by a two-compartment open model. The mean peak plasma levels of imipenem 30 min postinfusion were 55.4 and 27.2 micrograms/ml, and the mean t1/2 beta values were 2.1 and 1.8 h at doses of 25 and 15 mg/kg, respectively. The calculated volume of distribution was 0.41 liters/kg. In two patients from whom cerebrospinal fluid was obtained 1.5 h postinfusion, imipenem levels were 5.6 and 1.1 micrograms/ml at doses of 25 and 15 mg/kg, respectively, representing 10 and 4% of the 1-h serum levels. No side effects attributable to a single dose of imipenem-cilastatin were noted.

摘要

对10名1至8日龄的新生儿评估了亚胺培南(N-甲酰亚胺基硫霉素)(一种β-内酰胺类抗生素)与西司他丁(一种肾脱氢肽酶I抑制剂)联合使用时的单剂量药代动力学。亚胺培南-西司他丁组合在15分钟内静脉给药,剂量为15或25mg/kg。通过高压液相色谱法测定血清、尿液和脑脊液(如有)中的药物浓度,并采用二室开放模型描述药物的血浆处置情况。输注后30分钟时,亚胺培南的平均血浆峰浓度在25mg/kg和15mg/kg剂量下分别为55.4和27.2μg/ml,平均t1/2β值分别为2.1和1.8小时。计算得出的分布容积为0.41升/千克。在输注后1.5小时获取脑脊液的两名患者中,亚胺培南浓度在25mg/kg和15mg/kg剂量下分别为5.6和1.1μg/ml,分别占1小时血清浓度的10%和4%。未观察到单剂量亚胺培南-西司他丁所致的副作用。

相似文献

1
Single-dose pharmacokinetics of imipenem-cilastatin in neonates.亚胺培南-西司他丁在新生儿中的单剂量药代动力学。
Antimicrob Agents Chemother. 1985 Apr;27(4):511-4. doi: 10.1128/AAC.27.4.511.
2
Pharmacokinetics of imipenem-cilastatin in neonates.亚胺培南-西司他丁在新生儿中的药代动力学。
Antimicrob Agents Chemother. 1985 Apr;27(4):431-5. doi: 10.1128/AAC.27.4.431.
3
Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis.亚胺培南与西司他丁在囊性纤维化患者中的药代动力学
Antimicrob Agents Chemother. 1985 Apr;27(4):583-8. doi: 10.1128/AAC.27.4.583.
4
Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin.碳青霉烯类,一类新型β-内酰胺抗生素。亚胺培南/西司他丁的发现与研发。
Am J Med. 1985 Jun 7;78(6A):3-21. doi: 10.1016/0002-9343(85)90097-x.
5
The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.亚胺培南(硫霉素-甲脒)和肾脏脱氢肽酶抑制剂西司他丁钠在正常受试者和肾衰竭患者中的药代动力学。
Br J Clin Pharmacol. 1984 Aug;18(2):183-93. doi: 10.1111/j.1365-2125.1984.tb02451.x.
6
Pharmacokinetics and tolerance after repeated doses of imipenem/cilastatin in patients with severe renal failure.
J Antimicrob Chemother. 1986 Dec;18 Suppl E:115-20. doi: 10.1093/jac/18.supplement_e.115.
7
An overview of the pharmacology of imipenem/cilastatin.
J Antimicrob Chemother. 1986 Dec;18 Suppl E:79-92. doi: 10.1093/jac/18.supplement_e.79.
8
Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.N-甲酰亚胺基硫霉素脱氢肽酶抑制剂共同给药对N-甲酰亚胺基硫霉素(MK0787)尿回收率的影响
Antimicrob Agents Chemother. 1983 Feb;23(2):300-7. doi: 10.1128/AAC.23.2.300.
9
Single-dose pharmacokinetics of imipenem-cilastatin in pediatric patients.
Pediatr Pharmacol (New York). 1986;5(4):273-9.
10
[Pharmacokinetic and clinical studies with imipenem/cilastatin sodium in the pediatric field. Pediatric Study Group for Imipenem/Cilastatin Sodium].亚胺培南/西司他丁钠在儿科领域的药代动力学和临床研究。亚胺培南/西司他丁钠儿科研究组
Jpn J Antibiot. 1986 Jul;39(7):1912-37.

引用本文的文献

1
Predicting Volume of Distribution in Neonates: Performance of Physiologically Based Pharmacokinetic Modelling.预测新生儿的分布容积:基于生理学的药代动力学建模的性能
Pharmaceutics. 2023 Sep 19;15(9):2348. doi: 10.3390/pharmaceutics15092348.
2
Evaluation of evidence for pharmacokinetics-pharmacodynamics-based dose optimization of antimicrobials for treating Gram-negative infections in neonates.基于药代动力学-药效学的抗菌药物剂量优化用于治疗新生儿革兰氏阴性菌感染的证据评估。
Indian J Med Res. 2017 Mar;145(3):299-316. doi: 10.4103/ijmr.IJMR_723_15.
3
Comparative pharmacokinetics of the carbapenems: clinical implications.碳青霉烯类药物的比较药代动力学:临床意义。
Clin Pharmacokinet. 2000 Sep;39(3):185-201. doi: 10.2165/00003088-200039030-00002.
4
Neonatal Klebsiella pneumonia sepsis and imipenem/cilastatin.新生儿克雷伯菌肺炎败血症与亚胺培南/西司他丁
Indian J Pediatr. 1998 Jan-Feb;65(1):121-9. doi: 10.1007/BF02849703.
5
Antibiotics in neonatal infections: a review.新生儿感染中的抗生素:综述
Drugs. 1999 Sep;58(3):405-27. doi: 10.2165/00003495-199958030-00003.
6
Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.亚胺培南/西司他丁。对其抗菌活性、药代动力学特性及治疗效果的综述。
Drugs. 1987 Mar;33(3):183-241. doi: 10.2165/00003495-198733030-00001.
7
Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.抗菌化疗中酶抑制剂的临床药代动力学
Clin Pharmacokinet. 1988 Sep;15(3):133-64. doi: 10.2165/00003088-198815030-00001.
8
Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life.亚胺培南与西司他丁在出生后第一周早产儿中的临床药理学
Antimicrob Agents Chemother. 1990 Jun;34(6):1172-7. doi: 10.1128/AAC.34.6.1172.
9
Clinical pharmacokinetics of antibacterial drugs in neonates.抗菌药物在新生儿中的临床药代动力学。
Clin Pharmacokinet. 1990 Oct;19(4):280-318. doi: 10.2165/00003088-199019040-00003.

本文引用的文献

1
MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.MK0787(N-亚胺甲酰硫霉素):体内外活性评估
Antimicrob Agents Chemother. 1980 Jun;17(6):993-1000. doi: 10.1128/AAC.17.6.993.
2
Risk factors for the development of auditory toxicity in patients receiving aminoglycosides.接受氨基糖苷类药物治疗的患者发生耳毒性的危险因素。
J Infect Dis. 1984 Jan;149(1):23-30. doi: 10.1093/infdis/149.1.23.
3
Determination of imipenem and cilastatin in serum by high-pressure liquid chromatography.用高效液相色谱法测定血清中的亚胺培南和西司他丁。
Antimicrob Agents Chemother. 1984 Jul;26(1):78-81. doi: 10.1128/AAC.26.1.78.
4
Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.N-甲酰亚胺基硫霉素脱氢肽酶抑制剂共同给药对N-甲酰亚胺基硫霉素(MK0787)尿回收率的影响
Antimicrob Agents Chemother. 1983 Feb;23(2):300-7. doi: 10.1128/AAC.23.2.300.
5
Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.N-甲酰亚胺基硫霉素(MK0787)在人体中的药代动力学和耐受性。
Antimicrob Agents Chemother. 1983 Feb;23(2):293-9. doi: 10.1128/AAC.23.2.293.
6
Kanamycin dosage in newborn infants.新生儿卡那霉素的剂量
J Pediatr. 1976 Aug;89(2):313-4. doi: 10.1016/s0022-3476(76)80477-5.
7
A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group.
J Pediatr. 1976 Jul;89(1):66-72. doi: 10.1016/s0022-3476(76)80929-8.